The Medical and Surgical Practice of NaProTECHNOLOGY, 2004
Chapter 88: Cost-Effectiveness of NaProTECHNOLOGY
Author affiliations
- Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska. ROR
Abstract
An economic analysis of NaProTECHNOLOGY compares the total treatment costs and cost-per-live-birth outcomes against assisted reproductive technologies, including IVF, drawing on outcome data from the Pope Paul VI Institute to demonstrate that NaPro's higher per-cycle success rates yield a favorable cost-effectiveness ratio despite comparable or lower upfront expenditures. Because NaProTECHNOLOGY identifies and corrects underlying pathology rather than bypassing it, its resource utilization model supports long-term gynecological health benefits that IVF cannot provide, making the economic case inseparable from the clinical one.
Topics
Cost-effectiveness analysis: NaProTechnology vs. conventional careInfertility treatment cost: IVF vs. NaProTechnology per successful pregnancyCreighton Model System cost vs. contraceptive methodsPrematurity prevention: national medical cost burden and projected savingsPremenstrual syndrome: treatment cost and workplace productivityInfertility insurance coverage: cost per member per month